Evidence map›Paper›PMID 42479460›Full record

ArticleThe Journal of clinical investigation2026

Efferocytosis activates a DNMT3A-mediated oxidized DNA repair pathway to enable tissue resolution.

Kleopatra Avrampou, Santosh R Sukka, David Ngai, Patrick B Ampomah, Xiaobo Wang, George Kuriakose, Jacob Glass, Bernhard Dorweiler, Hanna Winter, Lars Maegdefessel and 3 more

Abstract read
In one paragraph

Article in The Journal of clinical investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kleopatra AvrampouDepartment of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
Santosh R SukkaDepartment of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
David NgaiDepartment of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
Patrick B AmpomahDepartment of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
Xiaobo WangDepartment of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
George KuriakoseDepartment of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
Jacob GlassCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Bernhard DorweilerDepartment of Vascular and Endovascular Surgery, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
Hanna WinterInstitute of Molecular Vascular Medicine, TUM Klinikum, Technical University of Munich, Munich, Germany.
Lars MaegdefesselDepartment of Physiology and Cellular Biophysics and.
Hanrui ZhangDepartment of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
Aaron D VinyDepartment of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
Ira TabasDepartment of Medicine, Columbia University Irving Medical Center, New York, New York, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Efferocytosis, the clearance of apoptotic cells by macrophages, promotes tissue resolution. Efficient resolution requires efferocytosis-induced macrophage proliferation (EIMP) to expand pro-resolving macrophages. Here, we show that efferocytosis activates base excision repair (BER) to remove 8-OHdG from DNA, enabling EIMP. Mechanistically, efferocytosis promotes poly(ADP-ribose) polymerase 1 (PARP1) chromatin binding and PARylation to facilitate DNA repair complex assembly and increases nuclear MutT homolog 1 (MTH1) (gene NUDT1), which hydrolyzes 8-OHdG. Both processes require DNA-methyltransferase-3A (DNMT3A), which is activated during efferocytosis. Using a model in which dexamethasone-induced thymocyte apoptosis triggers efferocytosis-mediated thymic repair, we showed that DNMT3A was required for increases in nuclear PARP1/MTH1, oxidized DNA suppression, EIMP in thymic macrophages, and thymic repair. We next studied a human-relevant model of atherosclerosis regression, whereby efferocytosis drove protective lesional fibrous cap thickening. We compared WT mice with a model of DNMT3A clonal hematopoiesis (CH), in which loss-of-function DNMT3A mutations promoted atherosclerotic disease. Atherosclerosis regression in WT mice led to decreased nuclear 8-OHdG and increased nuclear PARP1/MTH1 and EIMP in lesional macrophages and fibrous cap thickening, all of which were impaired in DNMT3A-CH regression. These findings reveal that efferocytosis initiates a BER pathway to allow macrophage proliferation for tissue resolution, with possible therapeutic relevance to atherosclerosis regression and DNMT3A-CH.

Indexed as

DNA (Cytosine-5-)-MethyltransferasesDNA RepairEfferocytosisMacrophagesAnimalsApoptosisDNA Methyltransferase 3AExcision RepairHumansMiceMice, Inbred C57BLMice, KnockoutPoly (ADP-Ribose) Polymerase-1ThymocytesDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADNMT3A protein, humanDnmt3a protein, mouseParp1 protein, mousePoly (ADP-Ribose) Polymerase-1AtherosclerosisCell biologyMacrophagesVascular biology

Identifiers

PMID42479460
PMCPMC13668614

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.